Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
503 KH-801, a differentated humanized anti-CD24 antibody, potentiates the effects of immunomodulatory and anti-tumor activity in preclinical cancer models with favorable safety profiles
Compose a Response to This Article
Other responses
No responses have been published for this article.
